Citations

Clear

3138 citation(s) found for "Smith, M".

Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling
Roulstone, Victoria , Kyula, Joan, Appleton, Elizabeth , Bommareddy, Praveen K. , Patrikeev, Anton , Jones, Sylwia , Kuncheria, Linta, Hak, Charleen ML Chan Wah, Foo, Shane Siang Chin, Baldock, Holly , Wongariyapak, Amarin , Leslie, Isla, Pickering, Robert J. , Zierhut, Christian , Smith, Henry G, Mohan, Nitya , Murano, Carmen , Hubbard, Lisa C. , Patin, Emmanuel C. , Gkantalis, Jim, Pedersen, Malin , Layzell, Scott , Mannion, Jonathan , Fernando, Winnie , Meier, Pascal, Vile, Richard, Melcher, Alan , Coffin, Robert S., Harrington, Kevin J. , Foo, Shane , Hak, Charleen Chan Wah , Chan Wah Hak, Charleen Ml , Pickering, Robert , Dean, Isaac , Patin, Emmanuel C , Gkantalis, Jim , Pedersen, Malin , McLaughlin, Martin , Mannion, Jonathan , Melcher, Alan A , Harrington, Kevin , Kyula, Joan , Smith, Henry George , Dean, Isaac , Mansfield, David , McLaughlin, Martin , Goicoechea, Maria , Meier, Pascal , Vile, Richard G.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 3, 2026 | Volume: 14 | Issue: 3 | Pages: e013692

10.1136/jitc-2025-013692 | PMID 41775431 Get It

Background Antitumor immune responses induced by oncolytic immunotherapy (OI) are often followed by upregulation of programmed death-ligand 1 (PD-L1). As such, the combination of OI with blockade of the programmed cell death protein-1 (PD-1)/PD-L1 axis has demonstrated therapeutic activity in preclinical and clinical trials. The purpose of this study is to understand further the immune-mediated mechanism of interaction between oncolytic viruses and anti-PD-1 therapy. Methods Tumor cells and immune cells (splenocytes) were cultured separately, or in co-culture with vusolimogene oderparepvec, an oncolytic herpes simplex virus expressing the fusogenic gibbon-ape leukemia virus-fusogenic membrane glycoprotein protein (GALV) and granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as RP1. Viral replication, interferon (IFN) responses and PD-L1 expression were analyzed using wild-type, IFNAR1, TNFAR1 and STING knockout splenocytes. In vivo studies evaluated immune cell infiltrates into the tumor following RP1 administration with anti-PD-1 therapy. Results RP1 replication was evident in tumor cells but not splenocytes. This was also accompanied by upregulated IFN expression in cultured splenocytes that was absent in cultured tumor cells. However, when these cell types were co-cultured, splenocytes mediated an interferon response to RP1 via STING that was transmitted to tumor cells in a non-touch-dependent manner. Tumor cells responded to these input signals via upregulation of cell surface major histocompatibility complex-I and PD-L1 through tumor intrinsic JAK-STAT signaling. In vivo, an IFN signature was observed following intratumoral injection of RP1, both in injected and non-injected tumors, which was further increased when combined with anti-PD-1 therapy. Marked upregulation of PD-L1 was observed in tumors injected with RP1 accompanied by the recruitment of CD11b+Ly6G+neutrophils into the tumor microenvironment, which stained positive for PD-L1. Conclusion Overall, the data demonstrate that RP1 remodels the tumor microenvironment through a combination of direct and indirect effects on both tumor and immune cells, resulting in an overall more inflamed phenotype.
Contact Derm Nursing Alliance
Richardson, D B, Smith, Mary C., Richardson, Donna, Smith, Mary Ellin

Mayo Clinic

Dermatitis® | March 2, 2026 | Volume: 17 | Issue: 2 | Pages: 100-100

10.2310/6620.2006.x0002q Get It

Recurrent Stroke in Patients With Cryptogenic Stroke and Left Ventricular Injury: The Cardiac Abnormalities in Stroke Prevention and Recurrence (CASPR) Study
Sharma, Richa, McNamara, Katelyn F. , Goicoechea, Elena Badillo, Bowman, Anna , Coevering, Russell J. Van , Chen, Lucia , Penckofer, Mary, Singh, Eesha , Kerrigan, Deborah, Nahab, Fadi, Glover, Patrick , Krishnaiah, Balaji , Yaghi, Shadi, Khasiyev, Farid, Lineback, Christina, Melkumova, Emiliya , Nguyen, Thanh N., Thompson, Sean, Daniel, Jean-Philippe Auguste, Aziz, Yasmin, Alvi, Muhammad , Herpich, Franziska , Shahrivari, Mahan, Chionatos, Rafail , Elangovan, Cheran, Kang, Jieun, Zha, Alicia , Farooqui, Mudassir, Rothstein, Aaron, Khan, Farhan, Smith, Matthew , Brown, Samantha, Qdais, Ahmad Abu, Liebeskind, David S., Abburi, Nandini , Rozental, Stefano, Nedelcu, Simona , Thon, Jesse M., Stretz, Christoph, Thottempudi, Neeharika, Yu, Wenzheng, Eklund, Kelsey , Linares, Guillermo, Havenon, Adam de, Siegler, James E., Liebeskind, David S. , Sharma, Richa , Brown, Samantha , Lineback, Christina , Penckofer, Mary , Kerrigan, Deborah , Badillo‐Goicoechea, Elena , Sharma, Richa , Goicoechea, Elena Badillo , Van Coevering, Russell J , Penckofer, Mary , Kerrigan, Deborah , Aboul-Nour, Hassan , Nahab, Fadi B , Krishnaiah, Balaji , Yaghi, Shadi , Khasiyev, Farid , Lineback, Christina M , Melkumova, Emiliya , Culbertson, Collin J , Nguyen, Thanh N , Jillella, Dinesh V , Aziz, Yasmin , Herpich, Franziska , Chionatos, Rafail A , Elangovan, Cheran , Zha, Alicia , Farooqui, Mudassir , Rothstein, Aaron , Khan, Farhan , Smith, Matthew M , Brown, Samantha J , Abu Qdais, Ahmad , Liebeskind, David S. , Abburi, Nandini , Nedelcu, Simona , Thon, Jesse , Stretz, Christoph , Eklund, Kelsey , Linares, Guillermo , de Havenon, Adam H , Siegler, James E , Daniel, Jean-Philippe Auguste , Nour, Hassan Aboul , Yaghi, Shadi , Nguyen, Thanh N. , Jillella, Dinesh , Aziz, Yasmin , Elangovan, Cheran , Rothstein, Aaron , Khan, Farhan , Rozental, Stefano Freitas Andrade, Thon, Jesse , Stretz, Christoph , Thottempudi, Neeharika , Yu, Wenzheng, Linares, Guillermo , Havenon, Adam de , Siegler, James E.

Mayo Clinic

Stroke | March 2, 2026 | Volume: 57 | Issue: 5 | Pages: 1175-1186

10.1161/strokeaha.125.053755 | PMID 41766531 Get It

BACKGROUND: Left ventricular (LV) dysfunction is a potential cardioembolic source of ischemic stroke, but its role in recurrent stroke risk and treatment response remains unclear. We explore whether LV injury associates with the risk of recurrent stroke and modifies the association between anticoagulation and stroke recurrence using real-world data. METHODS: We performed a multicenter, retrospective study of Cardiac Abnormalities in Stroke Prevention and Recurrence cohort across 27 US sites. Patients with LV ejection fraction ≥20% were included. LV injury, defined as LV ejection fraction 20% to 40% and wall motion abnormality, was the primary exposure and treatment effect modifier. The treatment of interest was anticoagulant versus antiplatelet therapy. The composite outcome included recurrent stroke, major bleeding, or death. Outcomes were evaluated using unadjusted and inverse probability weighting adjusted Cox proportional hazards models, with treatment effect modification tested by LV injury status. RESULTS: Among 2685 patients enrolled, 2328 with complete data were analyzed (median age, 65 years; 49.8% female; median follow-up, 1.6 years). LV injury was present in 310 patients (13.3%). Overall, 535 events occurred: 258 recurrent ischemic strokes, 28 hemorrhagic strokes, 67 major hemorrhages, and 256 deaths. LV injury was associated with a higher unadjusted risk of the primary outcome (hazard ratio [HR], 1.51 [95% CI, 1.21–1.87]), though nonsignificant after inverse probability weighting adjustment (adjusted HR, 1.29 [95% CI, 0.97–1.70]). In the LV injury subgroup, anticoagulation versus antiplatelet therapy was associated with a lower risk of the primary outcome (adjusted HR, 0.24 [95% CI, 0.10–0.59]), relative to the non-LV injury subgroup (adjusted HR, 1.28 [95% CI, 0.83–1.95]; p[LV-interaction], 0.001). Similar interactions were seen for EF 20% to 40% (versus >40%; adjusted HR, 0.19 [95% CI, 0.04–0.86]; p[LV-interaction], 0.001) and wall motion abnormality (versus no wall motion abnormality; adjusted HR, 0.33 [95% CI, 0.15–0.73]). CONCLUSIONS: After cryptogenic stroke, anticoagulation in those with LV injury was associated with lower rates of recurrent stroke, major bleeding, and death. These findings warrant confirmation in a dedicated randomized controlled trial. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06398366.
Surgical Pathology of Diffuse Parenchymal Lung Disease in Adults With IgA Vasculitis or IgA Nephropathy
Moore, Samantha A. , Butt, Yasmeen M. , Tazelaar, Henry D. , Larsen, Brandon T. , Smith, Maxwell L. , Tazelaar, Henry D.

Mayo Clinic

American Journal of Surgical Pathology | March 2, 2026 | Volume: 50 | Issue: 5 | Pages: 579-588

10.1097/pas.0000000000002522 | PMID 41765695 Get It

IgA vasculitis (IgAV) and IgA nephropathy (IgAN) are closely related disorders that usually present in childhood. Pulmonary involvement is rare and histopathologic features thereof in adults are poorly understood. Institutional archives were searched for adults with IgAV or IgAN and diffuse parenchymal lung disease. Ten patients (6 men, median age 59 years) with lung tissue sampling were enrolled. Clinical history and pathology slides were reviewed. All patients were diagnosed with IgAV or IgAN before or concurrently with lung disease. Symptoms were nonspecific but hemoptysis was common. Radiologically, bilateral ground-glass opacities, consolidation, and reticulonodular densities were typical. Histologically, 6 cases (60%) featured acute or subacute diffuse alveolar hemorrhage (DAH) accompanied by definite (40%) or probable (20%) capillaritis. Two cases (20%) featured resolved DAH only, manifesting as alveolar hemosiderosis without other changes. And 2 cases featured organizing pneumonia without DAH. Five patients had a chronic interstitial pneumonia in the background, including 3 with nonspecific interstitial pneumonia (NSIP) and 2 with unclassifiable fibrosis. Findings were similar in IgAV versus IgAN. Of 4 patients with follow-up information, 2 died during hospitalization, one died 9 weeks later of secondary complications, and one was treated with rituximab and nintedanib and is alive 2 years later. To our knowledge, this is the largest series detailing pulmonary histopathologic findings in adults with IgAV or IgAN. Most cases show acute DAH with capillaritis; less commonly, old DAH, organizing pneumonia, NSIP, or unclassifiable fibrosis may be observed. Some patients do well with treatment but fatal cases also occur.
Calcium release channel deficiency syndrome in patients diagnosed with idiopathic ventricular fibrillation and decedents classified as sudden unexplained death in the young
Giammarino, Lucilla , Neves, Raquel , Tester, David J. , Bains, Sahej , Vizentin, Vanessa Karlinski , Bos, J. Martijn, Giudicessi, John, Ackerman, Michael J. , Bos, J. Martijn , Bos, Johan M , Neves, Raquel Almeida Lopes , Bains, Sahej , Giudicessi, John R.

Mayo Clinic

Europace | February 24, 2026 | Volume: 28 | Issue: 2 | Pages: No page available

10.1093/europace/euaf303 | PMID 41785165 Get It

Abstract Aims Calcium release channel deficiency syndrome (CRCDS) results from loss-of-function (LOF) variants in the RYR2-encoded type 2 ryanodine receptor (RyR2), predisposing patients to sudden cardiac arrest/death (SCA/SCD) without abnormalities on a stress electrocardiogram (ECG). Undetected CRCDS may underlie idiopathic ventricular fibrillation (IVF) and sudden unexplained death in the young (SUDY). We aimed to determine the prevalence of potential CRCDS-causative RYR2 variants in IVF and SUDY. Methods and results We reviewed clinical evaluation and RYR2 genetic analysis of 169 IVF patients and 279 SUDY victims. Only ultra-rare (<0.005% in gnomAD) nonsynonymous RYR2 variants were considered potentially pathogenic. Among IVF patients, 6/169 (3%) overall—and 6/67 (9%) with exertion-related SCA—harboured an RYR2 variant and represent potential CRCDS cases. All exhibited normal resting and stress ECGs. Genetic analysis revealed six distinct RYR2 variants, two previously characterized as LOF. In SUDY, 31/279 victims (11%) had a RYR2 variant (30 unique variants), predominantly observed in exertion-related SCD 20/83 (24%) vs. rest-related 11/196 (6%). Of the 14 SUDY victims with functionally characterized RYR2 variants, five (2% of total cohort) had a LOF variant; among the 56 exertion-related SUDY cases, four (7%) had a LOF variant. Conclusion CRCDS may account for 3% of IVF overall and 9% of exertion-related SCA in IVF. Ultra-rare RYR2 variants may underlie up to 11% of SUDY, with 65% of RYR2-positive cases occurring during exertion. LOF-RYR2 variants may contribute to ≥7% of exercise-associated SUDY. Accurate identification of the underlying ryanodinopathy is essential for clinical management of affected patients.
Procedural Outcomes in Patients Undergoing Non-Cardiac Surgery with Cardiac Variant Amyloidosis
Smith, M. Cathie, Estévez, Maria , Chadha, Ryan M., Craver, Emily C. , Lyle, M., Shapiro, Anna Bovill , Smith, Michael A, Chadha, Ryan , Lyle, Melissa

Mayo Clinic

No container title available | February 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8867852/v1 Get It

Abstract Background: Amyloidosis is a complex disease with a multitude of sequalae, particularly with the variants that cause cardiac amyloidosis. There is minimal literature on the types of procedures these patients undergo and the associated postprocedural outcomes. This gap of knowledge makes it difficult for anesthesia providers to risk stratify amyloidosis patients. Methods: This is a single-center, retrospective chart review study performed at a tertiary care medical center that serves as a referral center for patients with amyloidosis. Patients with a known diagnosis of transthyretin (ATTR) or light chain (AL) amyloidosis who underwent procedures requiring anesthesia between January 1, 2018 and October 24, 2024 were included in the study. The primary outcome was 30-day all-cause mortality. Secondary outcomes included other postoperative complications and analysis of types of procedures requiring anesthesia. Results: During the study period, 160 patients underwent a total of 466 procedures requiring anesthesia. Overall, 30-day mortality rate for all encounters was 1.7% (2.7% AL vs 0.5% ATTR, OR 5.71). Endoscopy was the most common procedure, accounting for 26.6% of all procedures. At the patient level, several procedures were more common in ATTR patients including TEE/Cardioversions (21.7% vs 6.6%, p=0.008), electrophysiology (36.2% vs 9.9%, p<0.001), and neurosurgery (13.0% vs 3.3%, p=0.031). Conclusions: In conclusion, patients with amyloid variants that cause cardiac amyloidosis carry substantial postoperative risk when undergoing procedures, with a trend toward increased mortality in patients with AL compared to ATTR. Patients with ATTR are more likely to require neurosurgery and treatment of arrythmias than patients with AL. Additional studies are needed to determine specific diagnostic parameters to help optimize these patients in the future. Trial Registration : Not applicable. Not a clinical trial
Abstract PS1-02-17: Scrambler Therapy: a safe and effective way to treat chemo-induced neuropathy
Wang, Z., Loprinzi, C. L., Abdi, S., Strouse, T. B., Smith, T. J., Loprinzi, CL, Strouse, Thomas B. , Smith, Thomas J

Mayo Clinic

Clinical Cancer Research | February 20, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS1-02-17-PS1-02-17

10.1158/1557-3265.sabcs25-ps1-02-17 Get It

Abstract Background: Up to 68% of patients will experience CIPN. There are no FDA or ASCO recommended therapies. The pain (P), numbness (N), and tingling (T) can persist for month, years or even lifetime. Duloxetine reduces pain scores by 0.6-1.0 on the 0-10 scale but does not help N or T. Scrambler therapy (ST) is a novel form of neuromodulation that uses EKG electrodes on the dermatomes to capture the pain c-fiber receptors, and generate an action potential of “non-pain” information to replace the pain information. It appears to reset central sensitization by altering cerebral blood flow and re-establishing the balance of neuropeptides (e.g., NGF, GDNGF) in the blood (Smith et al NEJM 2023). Yet many professionals and patients are unaware of it. Methods: We reviewed all available studies. Results: Smith et al (2010, VCU) noted a 59% P reduction (5.8 to 2.4 at the end of 10 days (P&lt;0.0001)) in 16 subjects, and 4 had 0 pain at day 10. Pachman et al (2015, Mayo) in 37 subjects showed a 53% P reduction by day 10; a 44% reduction in T; and a 37% reduction in N. In a randomized trial of 50 patients using ST versus TENS (transcutaneous electrical nerve stimulation), Loprinzi et al (2020, Mayo), in a randomized trial, showed more than twice as many ST patients reported a 50% improvement (36-56%) vs. TENS (16-28%). At 8 weeks the reductions were important: 33%P, 28%N, 41%T. In a subsequent crossover trial (Childs 2021) of the TENS patients to ST, 6 of 12 ST patients achieved a 50% reduction in P and T. Smith et al (2021 Hopkins) did a randomized sham-controlled trial with 35 patients but observed no lasting effect; in retrospect, the electrodes and electrode placement were incorrect in this trial. Abdi et al (2024, MDACC) did a Phase II trial of ST in 10 patients and found symptoms of N, T, trouble walking, and disturbed sleep had significant improvements at 6 months. Worst pain was reduced at 6 months by 3 points. Pain medication use decreased by 70% at the end of treatment and by 42% at 6 months. Patient satisfaction was high (82%) and no adverse events with ST treatment were reported. Wang Z. et al (Hopkins, unpublished data 2025) showed a 60% reduction in pain (6.2 to 2) in twelve subjects, with one achieving complete remission. Strouse et al (2025, UCLA) will soon report similar results in over 60 patients. Wang E. et al (2023, Hopkins) reviewed 1152 patients treated with ST and found just 3 adverse events: one hematoma and two red spots under the EKG electrodes. The only other therapy that reduces all the symptoms of CIPN is spinal cord stimulation (Gupta 2024) but that is invasive, expensive, and can cause a multitude of adverse events. Conclusions: Scrambler Therapy is a safe and effective treatment for the P, N, and T of CIPN with rare and minimal side effects in a syndrome with no other effective treatment. It is hindered by reimbursement ($32/30 minutes, the same as TENS even though the technology is completely different). Scrambler Therapy should become more available in the future. Citation Format: Z. Wang, C. L. Loprinzi, S. Abdi, T. B. Strouse, T. J. Smith. Scrambler Therapy: a safe and effective way to treat chemo-induced neuropathy [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS1-02-17.
Continuous At-Home Monitoring of Nighttime Bed Behavior in Frontotemporal Dementia
Paolillo, Emily W., Wise, Amy, Kaye, Jeffrey A., Beattie, Zachary , Dhanam, Sreya, Casaletto, Kaitlin B. , Saloner, Rowan, Mendez, Mario F., Vandevrede, Lawren, Ljubenkov, Peter A. , Seeley, William W., Gorno-Tempini, Maria Luisa, Miller, Bruce L., Heuer, Hilary W. , Forsberg, Leah K., Kornak, John , Boeve, Bradley F., Boxer, Adam L., Rosen, Howard J., Walsh, Christine M., Staffaroni, Adam M., Abdullah, Muhammad, Apostolova, Liana , Ece, Bayram, Botha, Hugo, Brushaber, Danielle , Clark, David, Considine, Ciaran , Darby, R. Ryan , Day, Gregory S., Dickerson, Bradford, Dickson, Dennis, Domoto-Reilly, Kimiko, Dwosh, Emily , Faber, Kelley , Fagan, Anne M. , Fields, Julie A. , Fong, Jamie C., Foroud, Tatiana M., Galasko, Douglas R., Gavrilova, Ralitza, Gendron, Tania, Geschwind, Daniel, Ghoshal, Nupur , Goldman, Jill, Graff-Radford, Jonathan, Graff-Radford, Neill, Grant, Ian M., Grossman, Murray, Hales, Chadwick M., Hall, Matthew, Honig, Lawrence S., Hsiung, Ging-Yuek (Robin), Huang, Eric S., Huey, Edward D, Irwin, David, Johnson, Noah, Jones, David T., Kantarci, Kejal, Knopman, David, Kolander, Tyler, Kwan, Justin Y., Lago, Argentina Lario , Lapid, Maria, Lavigne, Shannon B., Lee, Suzee, Litvan, Irene, Lucente, Diane , Mackenzie, Ian R., Masdeu, Joseph C. , Massimo, Lauren , McGinnis, Scott, McMillan, Corey T., Mester, Carly, Miyagawa, Toji , Molden, Joie, Onyike, Chiadi, Pascual, Belen, Paulson, Henry, Petrucelli, Leonard, Pressman, Peter, Rademakers, Rosa, Ramanan, Vijay, Ramos, Eliana Marisa , Rankin, Katherine P., Rao, Meghana, Rascovsky, Katya, Rhoads, Kristoffer , Ritter, Aaron, Rogalski, Emily, Rojas, Julio C., Savica, Rodolfo, Snyder, Allison, Sullivan, Anna Campbell, Syrjanen, Jeremy, Tartaglia, M. Carmela, Taylor, Jack, Weintraub, Sandra, Wint, Dylan , Wong, Bonnie, Yokoyama, Jennifer, Mendez, Mario F. , VandeVrede, Lawren , Paolillo, Emily W. , Wise, Amy B. , Saloner, Rowan , Forsberg, Leah Kathleen, VandeVrede, Lawren , Mendez, Mario , Paolillo, Emily W , Kaye, Jeffrey , Au-Yeung, Wan-Tai Michael , Dhanam, Sreya , Seeley, William W. , Gorno‐Tempini, Maria Luisa , Forsberg, Leah K. , Kremers, Walter K. , Boeve, Bradley F. , Boxer, Adam L. , Rosen, Howard J. , Walsh, Christine M. , Staffaroni, Adam M. , Appleby, Brian S. , Barmada, Sami , Bozoki, Andrea C , Domoto‐Reilly, Kimiko , Galasko, Douglas , Gavrilova, Ralitza H. , Gendron, Tania F. , Geschwind, Daniel H., Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Grossman, Murray, Hales, Chadwick M. , Hall, Matthew , Honig, Lawrence, Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Knopman, David, Kwan, Justin , Lavigne, Shannon B., Léger, Gabriel C. , Litvan, Irene , Mackenzie, Ian R. , Masdeu, Joseph C , McMillan, Corey T. , Mester, Carly , Molden, Joie, Pantelyat, Alexander , Pascual, Belén , Petrucelli, Leonard , Pressman, Peter , Rademakers, Rosa, Rankin, Katherine P. , Rao, Meghana , Rascovsky, Katya, Roberson, Erik D. , Rogalskı, Emily , Rojas, Julio C. , Savica, Rodolfo , Snyder, Allison , Syrjanen, Jeremy A. , Tartaglia, Maria Carmela , Taylor, Jack C. , Tipton, Philip W. , Vandebergh, Marijne , Weıntraub, Sandra , Wong, Bonnie

Mayo Clinic

Neurology Open Access | February 18, 2026 | Volume: 2 | Issue: 1 | Pages: No page available

10.1212/wn9.0000000000000068 | PMID 41987885 Get It

Longitudinal peripheral blood multi-omic profiling in seropositive individuals identifies immune endotypes and predictive models for future rheumatoid arthritis conversion
Inamo, Jun , Bylinska, Aleksandra, Smith, M. D., Wright, Christian D., Stephens, Tayte, Feser, Marie L. , Striebich, Christopher C. , O'Dell, James R., Sparks, J., Davis, J. Michael , Graf, Jonathan , McMahon, Maureen , Solow, E. Blair, Forbess, Lindsy J., Tiliakos, Athan N., Horowitz, Diane , James, Judith A., Holers, V. Michael , Deane, KD, Guthridge, Joel M., Zhang, F., Sparks, Jeffrey A. , Sparks, Jeffrey A , Guthridge, Joel M , Zhang, Fan , Smith, Miles, Vanderlinden, Lauren A. , Wright, Christian, O’Dell, James R., Davis, John M., Solow, E. Blair , Forbess, Lindsy, Fox, David A. , Danila, Maria I. , Kay, Jonathan , James, Judith A. , Guthridge, Joel M.

Mayo Clinic

No container title available | February 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.12.26346058 | PMID 41757162 Get It

Abstract Individuals who have serum elevations of anti-cyclic citrullinated protein (anti-CCP) antibodies are at risk for developing rheumatoid arthritis (RA), yet immunologic factors that lead to a transition from pre- to clinical RA remain unclear. Here, we used materials from anti-CCP antibody-positive individuals enrolled in a clinical trial that evaluated the efficacy of hydroxychloroquine to prevent clinical RA, and performed multi-modal single-cell profiling (transcriptome, surface proteins, T/B-cell receptor sequencing, and chromatin accessibility) on samples obtained at baseline and at RA onset in those who developed clinical RA (Converters) or follow-up point in matched Nonconverters. At both baseline and follow-up, Converters had expansions of peripheral helper T (Tph) cells and CD8 + T cells expressing GZMK and GZMB , along with elevated potentially autoreactive T-cell receptors in CD4 + T cells compared to Nonconverters. Induction of age-associated B cell signatures was observed in B cells of Converters prior to RA onset. Epigenetic profiling further identified chromatin accessibility changes in Converters over time, particularly within myeloid and NK cells. Lastly, predictive modeling using baseline immune features, including Tph cells, GZMK + XCL1 + CD8 + , and GZMB + CD57 + CD8 + T cells, together with clinical features such as anti-CCP3 levels, RF-positivity, and HLA shared epitope status, stratified RA risk and predicted time to onset. These findings define immune endotypes in pre-RA that could serve as targets for future preventive interventions and be used to stratify the risk of developing clinical RA in anti-CCP antibody-positive individuals.